期刊
NEUROTHERAPEUTICS
卷 6, 期 2, 页码 323-336出版社
SPRINGER
DOI: 10.1016/j.nurt.2009.01.018
关键词
Epilepsy; seizures; antiepileptic drugs; blood-brain barrier; CNS delivery; drug delivery systems
资金
- NIDDK NIH HHS [R90 DK071501, T90 DK070068, T90 DK070068-05, R90 DK071501-05] Funding Source: Medline
- NINDS NIH HHS [R01 NS045236-04, R01 NS045236-01, R01 NS045236-03, R01 NS045236-05, R01 NS045236, R01 NS045236-02] Funding Source: Medline
Epilepsy results from aberrant electrical activity that can affect either a focal area or the entire brain. In treating epilepsy with drugs, the aim is to decrease seizure frequency and severity while minimizing toxicity to the brain and other tissues. Antiepileptic drugs (AEDs) are usually administered by oral and intravenous routes, but these drug treatments are not always effective. Drug access to the brain is severely limited by a number of biological factors, particularly the blood-brain barrier, which impedes the ability of AEDs to enter and remain in the brain. To improve the efficacy of AEDs, new drug delivery strategies are being developed; these methods fall into the three main categories: drug modification, blood-brain barrier modification, and direct drug delivery. Recently, all three methods have been improved through the use of drug-loaded nanoparticles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据